3.22% -1.285

Ionis Pharmaceuticals Inc (IONS)

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

Ionis Pharmaceuticals Inc (IONS)

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

Principal Financial Group Inc. Reduces Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

January 2026 Options Now Available For Ionis Pharmaceuticals - Nasdaq

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to Post Q3 2024 Earnings of ($0.92) Per Share, Leerink Partnrs Forecasts - MarketBeat

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - MSN

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - Zacks Investment Research

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering - Yahoo Finance

Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter

FY2028 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Increased by Analyst - MarketBeat

Ionis announces pricing of $500.3 million public offering - MSN

SEC Form 424B5 filed by Ionis Pharmaceuticals Inc. - Quantisnow

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down to $48.33 - MarketBeat

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Ionis Pharmaceuticals plans $500 million stock offering - Investing.com

Ionis Pharmaceuticals announces public stock offering - Investing.com

Ionis announces proposed public offering of common stock - The Malaysian Reserve

Ionis announces pricing of $500.3 million public offering - Financial Times

Ionis announces pricing of $500.3 million public offering - PR Newswire

Ionis Pharmaceuticals plans $500 million stock offering - Investing.com India

Ionis Pharmaceuticals plans $500 million stock offering By Investing.com - Investing.com Canada

Ionis Pharmaceuticals plans $500 million stock offering By Investing.com - Investing.com UK

Ionis announces proposed public offering of common stock - Financial Times

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by TD Asset Management Inc - MarketBeat

AstraZeneca Believes Size Matters In Amyloidosis - Scrip

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.68 Average PT from Brokerages - MarketBeat

EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow

EVP CLO & General Counsel O'Neil Patrick R. acquired $9,506 worth of shares (246 units at $38.64), increasing direct ownership by 0.51% to 48,873 units (SEC Form 4) - Quantisnow

IgA Nephropathy Market to Show Remarkable Growth Trends from - openPR

The Globe and Mail - The Globe and Mail

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth - openPR

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics - Barchart

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA - Quantisnow

Amendment: EVP, Finance & CFO Hougen Elizabeth L sold $107,105 worth of shares (2,162 units at $49.54), decreasing direct ownership by 2% to 92,868 units (SEC Form 4) - Quantisnow

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $15,731.20 in Stock - MarketBeat

Ionis Pharmaceuticals executive sells over $32k in stock By Investing.com - Investing.com Australia

Ionis Pharmaceuticals executive sells over $32k in stock - Investing.com

Ionis Pharmaceuticals executive sells over $32k in stock By Investing.com - Investing.com UK

EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow

Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online

Arrowhead Aims For Best-In-Class In FCS - Scrip

Lisanti Capital Growth LLC Sells 16,990 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is Privium Fund Management B.V.'s 9th Largest Position - MarketBeat

Nicola Wealth Management LTD. Buys 18,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Peregrine Capital Management LLC - MarketBeat

Ionis Pharmaceuticals (NASDAQ:IONS) Trading Down 4.3% - MarketBeat

Ionis to present at upcoming investor conferences - PR Newswire

Liontrust Investment Partners LLP Has $2.84 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Increased to $55.00 by Analysts at JPMorgan Chase & Co. - MarketBeat

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $55.00 - Defense World

Baillie Gifford & Co. Has $12.40 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding - Simply Wall St

Assenagon Asset Management S.A. Sells 247,037 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Familial Lipoprotein Lipase Deficiency Market Booming - openPR

Sumitomo Mitsui Trust Holdings Inc. Has $9.50 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Non-CME Corporate Forum sponsored by Ionis Pharmaceuticals, Inc. Long-Term Prophylactic Therapies for Hereditary Angioedema: Real-World Challenges and Opportunities to Optimize Patient Outcomes - PRIME® Continuing Medical Education

Sumitomo Mitsui Trust Holdings Inc. Sells 21,030 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Plasma Protease C1-Inhibitor Treatment Industry to Witness - openPR

Hereditary Angioedema Treatment Market 2032: FDA Approvals, - openPR

Ionis announces expanded licensing agreement with Otsuka in Asia - GuruFocus.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Swedbank AB - MarketBeat

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Swedbank AB - Defense World

Ionis to present at upcoming investor conferences - GuruFocus.com

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? - Yahoo Finance

Ionis announces the appointment of Michael Yang to Board of Dire - GuruFocus.com

Ionis Pharmaceuticals (STU:ISI) EV-to-Revenue : 7.57 (As of Aug. 14, 2024) - GuruFocus.com

RNAi Technology Market Booming Worldwide With Leading Key - openPR

Patient with rare neurodegenerative disorder improves with non-profit’s ASO therapy - Pharmaceutical Technology

Ähnlich wie IONS